Biofrontera (NASDAQ:BFRI) Posts Quarterly Earnings Results, Misses Estimates By $0.29 EPS

Biofrontera (NASDAQ:BFRI) announced its quarterly earnings data on Thursday. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.29), FiscalAI reports. Biofrontera had a negative return on equity of 1,236.11% and a negative net margin of 25.26%.The company had revenue of $10.08 million for the quarter, compared to analyst estimates of $10.25 million.

Here are the key takeaways from Biofrontera’s conference call:

• Biofrontera reported Q1 2026 product revenue of $10.1 million, up 17% year over year, driven by a 16% increase in Ameluz tube volume and a price increase implemented in late 2025.
• The new post-transaction cost structure materially improved profitability, with gross margin expanding to about 80% from 62% a year ago and management saying the company is tracking toward its 80%-85% long-term target.
• Cash used in operations was just $70,000 in the quarter, a sharp improvement from $4.1 million in Q1 2025, which management said supports its path to cash flow breakeven this year.
• The clinical/regulatory pipeline advanced on multiple fronts, including FDA acceptance of the supplemental NDA for superficial basal cell carcinoma with a PDUFA date of September 28, 2026, and positive phase III data for AK on the neck, trunk, and extremities supporting a planned sNDA filing in Q3 2026.
• Management also highlighted encouraging phase II acne data and said it expects to discuss a potential phase III program with the FDA later in 2026, while noting ongoing tariff and supply-chain monitoring because all products are imported from Europe.

Biofrontera Stock Down 4.4%

NASDAQ BFRI traded down $0.04 during trading on Friday, reaching $0.95. 88,807 shares of the company’s stock were exchanged, compared to its average volume of 372,161. The stock has a market cap of $11.35 million, a P/E ratio of -0.92 and a beta of 0.89. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.40 and a current ratio of 1.52. The company has a 50 day moving average price of $0.97 and a two-hundred day moving average price of $0.90. Biofrontera has a 1 year low of $0.54 and a 1 year high of $1.19.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $2.75.

Institutional Investors Weigh In On Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. Rosalind Advisors Inc. raised its stake in Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 976,448 shares of the company’s stock after acquiring an additional 332,055 shares during the period. Biofrontera accounts for approximately 0.3% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th largest position. Rosalind Advisors Inc. owned approximately 9.63% of Biofrontera worth $695,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.08% of the company’s stock.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.